In vivo studies of [125I]iodobenzamide and [11C]iodobenzamide: A ligand suitable for positron emission tomography and single photon emission tomography imaging of cerebral D2 dopamine receptors

Dean F. Wong, Alan A. Wilson, Catherine Chen, Elynne Minkin, Robert F. Dannals, Hayden T. Ravert, Patricia Sanchez‐Roa, Victor Villemagne, Henry N. Wagner

Research output: Contribution to journalArticle

Abstract

Iodobenzamide (IMB) labeled with either [11C] or [125I] was studied in mice and baboons. Pharmacological studies demonstrated an in vivo binding profile compatible with D2 dopamine receptors. Mouse biodistribution studies with both [11C]IMB and [125I]IMB showed a similar brain distribution of radioactivity. Mouse [125I]IMB studies with amphetamine and reserpine pretreatment suggested that IMB may be less susceptible to endogenous dopamine competition for D2 receptor binding in vivo as compared to raclopride. Preliminary baboon studies showed haloperidol competition for IMB binding sites. © 1992 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)236-241
Number of pages6
JournalSynapse
Volume12
Issue number3
DOIs
StatePublished - Nov 1992

Keywords

  • Endogenous dopamine
  • In vivo biodistribution
  • Radioactivity

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'In vivo studies of [<sup>125</sup>I]iodobenzamide and [<sup>11</sup>C]iodobenzamide: A ligand suitable for positron emission tomography and single photon emission tomography imaging of cerebral D<sub>2</sub> dopamine receptors'. Together they form a unique fingerprint.

  • Cite this